Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

İNCEL UYSAL P., YALÇIN B., ÖKTEM A.

DERI HASTALIKLARI VE FRENGI ARSIVI, cilt.51, sa.4, ss.124-128, 2017 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 51 Sayı: 4
  • Basım Tarihi: 2017
  • Doi Numarası: 10.4274/turkderm.65983
  • Dergi Adı: DERI HASTALIKLARI VE FRENGI ARSIVI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.124-128
  • Anahtar Kelimeler: Bullous pemphigoid, immunotherapy, omalizumab, SERUM-LEVELS, IGE, AUTOANTIBODIES, AUTOIMMUNITY, ASSOCIATION, MANAGEMENT, RISK
  • Ankara Üniversitesi Adresli: Evet

Özet

Background and Design: In the era of biological therapies, omalizumab (OMZ), a monoclonal antibody which inhibits IgE, has been postulated to be effective in the treatment of bullous pemphigoid (BP). We report our dinical experience with the use of OMZ in the treatment of BR